Disposition of 10000 shares by Welgus Howard G. of Arcutis Biotherapeutics at 9.2616 subject to Rule 16b-3
ARQT Stock | USD 12.25 0.52 4.07% |
Slightly above 76 percent of Arcutis Biotherapeutics' private investors are selling. The analysis of the overall investor sentiment regarding Arcutis Biotherapeutics suggests that a fairly large number of traders are terrified. Arcutis Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Arcutis Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Arcutis |
Filed transaction by Arcutis Biotherapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Arcutis Biotherapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Arcutis Biotherapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Arcutis Biotherapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Arcutis Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Arcutis Biotherapeutics Fundamental Analysis
We analyze Arcutis Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Arcutis Biotherapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Arcutis Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcutis Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Arcutis Biotherapeutics Related Equities
INZY | Inozyme Pharma | 0.68 | ||||
PBYI | Puma Biotechnology | 0.68 | ||||
PTGX | Protagonist Therapeutics | 1.51 | ||||
DAWN | Day One | 2.66 | ||||
SNDX | Syndax Pharmaceuticals | 5.34 | ||||
IOVA | Iovance Biotherapeutics | 7.23 | ||||
ZNTL | Zentalis Pharmaceuticals | 10.57 | ||||
MRSN | Mersana Therapeutics | 14.18 |
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.